Oncolytics Biotech (ONCY) News Today $0.99 -0.03 (-2.94%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.00 +0.01 (+1.52%) As of 08/1/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ONCY Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Analysts Set Oncolytics Biotech Inc. (NASDAQ:ONCY) Target Price at $4.33August 2 at 2:06 AM | americanbankingnews.comOncolytics Biotech (ONCY) Projected to Post Earnings on ThursdayJuly 31 at 3:38 AM | marketbeat.comOncolytics Biotech Inc. (NASDAQ:ONCY) Given Average Rating of "Moderate Buy" by BrokeragesJuly 30, 2025 | marketbeat.comOncolytics Biotech® to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-EndJuly 29, 2025 | prnewswire.comOncolytics Biotech (NASDAQ:ONCY) Stock Price Up 3.8% - Time to Buy?July 29, 2025 | marketbeat.comCancer Surge Meets Funding Crunch as Breakthrough Biotechs Line Up Milestones in 2025July 24, 2025 | baystreet.caOncolytics Biotech Inc.: Oncolytics Biotech Regains Compliance with Nasdaq Trading RulesJuly 24, 2025 | finanznachrichten.deOncolytics Biotech Highlights Pelareorep’s Potential in Pancreatic Cancer at KOL EventJuly 23, 2025 | tipranks.comKey Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future PotentialJuly 23, 2025 | prnewswire.comOncolytics Biotech Regains Nasdaq Compliance as of July 22, 2025July 22, 2025 | tipranks.comOncolytics Biotech® Regains Compliance with Nasdaq Trading RulesJuly 22, 2025 | prnewswire.comOncolytics Biotech® Presents Aggregated Translational Data Providing Evidence of Pelareorep's Effectiveness Across Multiple Tumor TypesJuly 16, 2025 | prnewswire.comOncolytics Biotech Inc. (ONCY) - Yahoo Finance CanadaJuly 11, 2025 | ca.finance.yahoo.comUSA News Group: Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step UpJuly 10, 2025 | finanznachrichten.deOncolytics Biotech to Host Webinar on Pelareorep’s Potential in Cancer TreatmentJuly 10, 2025 | tipranks.comOncolytics Biotech® to Host Key Opinion Leader Discussion Focusing on Pancreatic and Gastrointestinal CancersJuly 10, 2025 | prnewswire.comOncolytics Biotech Highlights Promising Pelareorep Data in Cancer TreatmentJuly 10, 2025 | theglobeandmail.comGlobal Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies - The Globe and MailJuly 9, 2025 | theglobeandmail.comOncolytics Biotech® Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling StudiesJuly 8, 2025 | prnewswire.comOncolytics Biotech Inc. (NASDAQ:ONCY) Given Average Recommendation of "Moderate Buy" by AnalystsJuly 5, 2025 | marketbeat.comOncolytics Biotech Inc. (NASDAQ:ONCY) Receives Average Rating of "Moderate Buy" from BrokeragesJuly 5, 2025 | marketbeat.comOncolytics Biotech (NASDAQ:ONCY) Trading Down 3% - Should You Sell?July 1, 2025 | marketbeat.comOncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development StrategyJune 30, 2025 | prnewswire.comPrivate-Sector Oncology May Be the Market’s Best-Understood SecretJune 20, 2025 | baystreet.caUSA News Group: With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in OncologyJune 20, 2025 | finanznachrichten.deUSA News Group: Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is GoingJune 18, 2025 | finanznachrichten.deOncolytics Biotech® Names New CEO to Accelerate Momentum in Immunotherapy ProgramsJune 11, 2025 | prnewswire.comOncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation CapabilitiesMay 23, 2025 | prnewswire.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Immunome (IMNM), Oncolytics Biotech (ONCY) and Hookipa Pharma (HOOK)May 18, 2025 | theglobeandmail.comJones Trading Downgrades Oncolytics Biotech (ONCY)May 17, 2025 | msn.comOncolytics Biotech Inc.: Oncolytics Biotech Reports First Quarter Financial Results and Highlights Clinical MomentumMay 17, 2025 | finanznachrichten.deOncolytics Biotech Inc. (NASDAQ:ONCY) Q1 2025 Earnings Call TranscriptMay 16, 2025 | insidermonkey.comOncolytics Biotech Inc. (ONCY) Q1 2025 Earnings Call TranscriptMay 14, 2025 | seekingalpha.comOncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical MomentumMay 14, 2025 | prnewswire.comOncolytics Biotech to Discuss Q1 2025 Financial Results on May 14May 8, 2025 | tipranks.comOncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational HighlightsMay 6, 2025 | prnewswire.comOncolytics Biotech, Inc. Common Shares (ONCY) Latest After Hours TradesMay 4, 2025 | nasdaq.comOncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of ActionApril 24, 2025 | prnewswire.comAs Cancer Rates Climb, Wall Street Turns Its Gaze Toward New Frontiers in Cancer TreatmentsApril 14, 2025 | baystreet.caOncolytics Biotech Secures $20 Million Funding for Pelareorep DevelopmentApril 10, 2025 | tipranks.comOncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni CapitalApril 10, 2025 | prnewswire.comOncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic CancersApril 10, 2025 | prnewswire.comWhat is HC Wainwright's Estimate for ONCY FY2027 Earnings?March 14, 2025 | marketbeat.comLeede Financial Has Positive Outlook of ONCY FY2025 EarningsMarch 14, 2025 | marketbeat.comHC Wainwright Cuts Earnings Estimates for Oncolytics BiotechMarch 13, 2025 | marketbeat.comMaxim Group Issues Pessimistic Forecast for Oncolytics Biotech (NASDAQ:ONCY) Stock PriceMarch 11, 2025 | marketbeat.comOncolytics Biotech's (ONCY) Buy Rating Reiterated at HC WainwrightMarch 11, 2025 | marketbeat.comRoyal Bank of Canada Cuts Oncolytics Biotech (NASDAQ:ONCY) Price Target to $5.00March 11, 2025 | marketbeat.comOncolytics price target lowered to $3 from $5 at MaximMarch 10, 2025 | markets.businessinsider.comOncolytics Biotech Inc. (NASDAQ:ONCY) Q4 2024 Earnings Call TranscriptMarch 8, 2025 | msn.com Get Oncolytics Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for ONCY and its competitors with MarketBeat's FREE daily newsletter. Email Address ONCY Media Mentions By Week ONCY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ONCY News Sentiment▼0.200.45▲Average Medical News Sentiment ONCY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ONCY Articles This Week▼52▲ONCY Articles Average Week Get Oncolytics Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for ONCY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies COMPASS Pathways News Today Eton Pharmaceuticals News Today Aquestive Therapeutics News Today SNDL News Today Arcturus Therapeutics News Today iTeos Therapeutics News Today Vigil Neuroscience News Today CryoPort News Today Humacyte News Today Astria Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ONCY) was last updated on 8/3/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredInvestigating the Most Controversial Stock on EarthTesla’s wild price swings may not be random after all. Hedge fund veteran Larry Benedict has uncovered a st...Brownstone Research | SponsoredThis New Rule Could Change EverythingA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredSell these "safe" blue chips immediatelyInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncolytics Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncolytics Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ONCY Stock Alerts